Floatz logo

Carboplatin

HBV

Universita di VeronaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the HBV cohort.

Asset / SponsorPhaseRating
tenofovir
Ruijin Hospital
Phase 4BB
Sorafenib
Mina Alpha Limited
Phase 2B
sb-497115-gr
GlaxoSmithKline
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Universita di Verona
Phase 2CCC
Nivolumab
Universita di Verona
Phase 2CCC

View all 11 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →